New hope for arthritis sufferers: filgotinib shows promise in korean trial

NCT ID NCT06625242

Completed Disease control Sponsor: Eisai Korea Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug filgotinib (Jyseleca) in 118 Korean adults with rheumatoid arthritis. The goal was to see how many patients experienced at least a 20% improvement in symptoms after 12 weeks of treatment. The trial is complete, and results will help determine if filgotinib is a safe and effective option for this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: filgotinib (Jyseleca)
What this could lead to: If successful, this could confirm filgotinib as a safe and effective option for controlling rheumatoid arthritis symptoms in Korean patients.
What could go wrong: This is a single-arm, open-label study with no placebo group, so results may be less reliable. It is also limited to Korean patients, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Eisai site #01

Busan, South Korea
Eisai site #02

Gwangju, South Korea
Eisai site #03

Seoul, South Korea
Eisai site #04

Seoul, South Korea
Eisai site #05

Seoul, South Korea
Eisai site #06

Daejeon, South Korea
Eisai site #07

Seoul, South Korea
Eisai site #08

Seoul, South Korea
Eisai site #09

Daegu, South Korea
Eisai site #10

Seoul, South Korea
Eisai site #11

Anyang-si, South Korea
Eisai site #12

Daegu, South Korea
Eisai site #13

Incheon, South Korea
Eisai site #14

Seoul, South Korea
Eisai site #15

Guri-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.